Clinical characteristics and successful treatment outcomes of children and adolescents with Kaposi sarcoma in Southwestern Tanzania
| Autor: | Parth S. Mehta, Erin C. Peckham-Gregory, Michael E. Scheurer, Nader Kim El-Mallawany, B M Malingoti, Jeremy S. Slone, Jason M. Bacha, Liane R. Campbell |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pediatrics
medicine.medical_specialty Adolescent medicine.medical_treatment Tanzania Acquired immunodeficiency syndrome (AIDS) Seroepidemiologic Studies Interquartile range Median follow-up medicine Humans Seroprevalence Lost to follow-up Child Sarcoma Kaposi Retrospective Studies biology business.industry Immunosuppression Hematology medicine.disease biology.organism_classification Treatment Outcome Oncology Pediatrics Perinatology and Child Health Cohort business |
| Zdroj: | Pediatric Hematology and Oncology. 39:28-47 |
| ISSN: | 1521-0669 0888-0018 |
| Popis: | The HIV/AIDS epidemic has driven the rise in cases of Kaposi sarcoma (KS) among children and adolescents living with HIV in countries with high Human gammaherpesvirus 8 (HHV-8) seroprevalence, such as Tanzania, where specialized oncology programs are sparse. Consequently, descriptions of successful treatment of KS in children and adolescents by general pediatricians are important. A retrospective analysis was performed of children and adolescents diagnosed with KS and treated with chemotherapy and combination antiretroviral therapy (cART) at the Baylor College of Medicine Children's Foundation Tanzania Center of Excellence - Mbeya between 2011 and 2017. Sixty-one patients were diagnosed with KS with a median age of 12.6 years (interquartile range (IQR) 9.4 - 15.5). Diagnosis was confirmed by histopathology in 36% (22/61). Among HIV positive patients (59/61), 78% (46/59) were on cART at KS diagnosis. Severe immunosuppression was present in 63% (35/56) of those with CD4 data and 44% (27/61) had SAM. Advanced-stage T1 disease was present in 64% (39/61), including 28% (17/61) with visceral/disseminated KS. Two-year estimated overall survival (OS) was 72% (95% Confidence Interval (CI): 58%-82%) and median follow up for survivors was 25.7 months (IQR 14.2-53.8). No patients were lost to follow up. Two-year OS was 63% (95% CI: 44%-77%) in patients with severe immune suppression and 60% (95% CI: 37%-76%) in patients with SAM. Among patients with visceral/disseminated KS, 53% (9/17) survived. This retrospective analysis demonstrated favorable outcomes in a complex cohort of children and adolescents with KS treated with chemotherapy by general pediatricians in Tanzania. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|